Share Price and Basic Stock Data
Last Updated: March 8, 2025, 10:47 am
| PEG Ratio | 0.00 |
|---|
Competitors of Solara Active Pharma Sciences Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| MPS Pharmaa Ltd | 6.71 Cr. | 3.51 | 4.33/3.05 | 0.80 | 0.00 % | 9.15 % | 34.9 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 2,663 Cr. | 244 | 390/192 | 50.6 | 20.5 | 0.27 % | 45.0 % | 33.8 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 53.1 Cr. | 71.5 | 94.9/32.1 | 18.0 | 11.9 | 0.00 % | 9.72 % | 3.44 % | 10.0 |
| Gujarat Inject (Kerala) Ltd | 38.0 Cr. | 26.0 | 29.0/8.74 | 38.8 | 6.64 | 0.00 % | 2.65 % | 2.08 % | 10.0 |
| Godavari Drugs Ltd | 70.4 Cr. | 93.5 | 155/79.0 | 11.4 | 55.4 | 0.00 % | 14.4 % | 15.5 % | 10.0 |
| Industry Average | 17,255.37 Cr | 1,081.84 | 42.42 | 185.80 | 0.37% | 16.00% | 16.32% | 6.27 |
Quarterly Result
| Metric | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 100.34 | 360.82 | 330.07 | 338.37 | 394.75 | 380.62 | 352.31 | 425.24 | 211.94 | 299.43 | 363.49 | 346.95 | 300.31 |
| Expenses | 197.18 | 347.29 | 317.52 | 310.80 | 349.75 | 331.85 | 333.19 | 387.61 | 373.63 | 289.67 | 321.57 | 285.64 | 242.63 |
| Operating Profit | -96.84 | 13.53 | 12.55 | 27.57 | 45.00 | 48.77 | 19.12 | 37.63 | -161.69 | 9.76 | 41.92 | 61.31 | 57.68 |
| OPM % | -96.51% | 3.75% | 3.80% | 8.15% | 11.40% | 12.81% | 5.43% | 8.85% | -76.29% | 3.26% | 11.53% | 17.67% | 19.21% |
| Other Income | 3.21 | 4.76 | 6.98 | 3.72 | 7.17 | 4.68 | 2.04 | -4.04 | -62.32 | -120.48 | 0.56 | 0.32 | 1.49 |
| Interest | 17.82 | 21.47 | 22.50 | 21.96 | 23.64 | 21.96 | 24.61 | 24.44 | 25.37 | 30.69 | 30.87 | 28.28 | 26.54 |
| Depreciation | 28.44 | 27.82 | 28.13 | 28.63 | 27.98 | 26.45 | 25.91 | 26.21 | 25.96 | 25.25 | 25.07 | 25.34 | 24.54 |
| Profit before tax | -139.89 | -31.00 | -31.10 | -19.30 | 0.55 | 5.04 | -29.36 | -17.06 | -275.34 | -166.66 | -13.46 | 8.01 | 8.09 |
| Tax % | 0.00% | -105.84% | -47.11% | -48.29% | 21.82% | 25.40% | -34.91% | 0.00% | 0.00% | 53.28% | 0.00% | 0.00% | 0.00% |
| Net Profit | -139.89 | 1.81 | -16.45 | -9.98 | 0.43 | 3.76 | -19.11 | -17.06 | -275.34 | -255.45 | -13.46 | 8.01 | 8.09 |
| EPS in Rs | -29.20 | 0.39 | -3.42 | -2.08 | 0.09 | 0.79 | -4.07 | -3.58 | -57.36 | -53.20 | -3.74 | 2.22 | 2.24 |
Last Updated: February 28, 2025, 5:02 pm
Below is a detailed analysis of the quarterly data for Solara Active Pharma Sciences Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:
- For Sales, as of Dec 2024, the value is ₹300.31 Cr.. The value appears to be declining and may need further review. It has decreased from 346.95 Cr. (Sep 2024) to ₹300.31 Cr., marking a decrease of 46.64 Cr..
- For Expenses, as of Dec 2024, the value is ₹242.63 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 285.64 Cr. (Sep 2024) to ₹242.63 Cr., marking a decrease of 43.01 Cr..
- For Operating Profit, as of Dec 2024, the value is ₹57.68 Cr.. The value appears to be declining and may need further review. It has decreased from 61.31 Cr. (Sep 2024) to ₹57.68 Cr., marking a decrease of 3.63 Cr..
- For OPM %, as of Dec 2024, the value is 19.21%. The value appears strong and on an upward trend. It has increased from 17.67% (Sep 2024) to 19.21%, marking an increase of 1.54%.
- For Other Income, as of Dec 2024, the value is ₹1.49 Cr.. The value appears strong and on an upward trend. It has increased from 0.32 Cr. (Sep 2024) to ₹1.49 Cr., marking an increase of ₹1.17 Cr..
- For Interest, as of Dec 2024, the value is ₹26.54 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 28.28 Cr. (Sep 2024) to ₹26.54 Cr., marking a decrease of 1.74 Cr..
- For Depreciation, as of Dec 2024, the value is ₹24.54 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 25.34 Cr. (Sep 2024) to ₹24.54 Cr., marking a decrease of 0.80 Cr..
- For Profit before tax, as of Dec 2024, the value is ₹8.09 Cr.. The value appears strong and on an upward trend. It has increased from 8.01 Cr. (Sep 2024) to ₹8.09 Cr., marking an increase of ₹0.08 Cr..
- For Tax %, as of Dec 2024, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00%.
- For Net Profit, as of Dec 2024, the value is ₹8.09 Cr.. The value appears strong and on an upward trend. It has increased from 8.01 Cr. (Sep 2024) to ₹8.09 Cr., marking an increase of ₹0.08 Cr..
- For EPS in Rs, as of Dec 2024, the value is 2.24. The value appears strong and on an upward trend. It has increased from ₹2.22 (Sep 2024) to 2.24, marking an increase of ₹0.02.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: March 7, 2025, 6:48 pm
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,310 |
| Expenses | 464 | 1,174 | 1,062 | 1,231 | 1,188 | 1,309 | 1,384 | 1,140 |
| Operating Profit | 57 | 213 | 260 | 386 | 81 | 134 | -95 | 171 |
| OPM % | 11% | 15% | 20% | 24% | 6% | 9% | -7% | 13% |
| Other Income | 2 | 12 | 27 | 29 | 16 | 22 | -185 | -118 |
| Interest | 25 | 82 | 78 | 84 | 75 | 90 | 105 | 116 |
| Depreciation | 34 | 83 | 94 | 109 | 112 | 111 | 103 | 100 |
| Profit before tax | 0 | 60 | 115 | 222 | -91 | -45 | -488 | -164 |
| Tax % | -70% | 1% | 0% | 0% | -36% | -50% | 16% | |
| Net Profit | 0 | 59 | 115 | 221 | -58 | -22 | -567 | -253 |
| EPS in Rs | 17.30 | 32.01 | 46.22 | -12.11 | -4.62 | -118.21 | -52.48 | |
| Dividend Payout % | 0% | 22% | 5% | 11% | 0% | -49% | 0% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 94.92% | 92.17% | -126.24% | 62.07% | -2477.27% |
| Change in YoY Net Profit Growth (%) | 0.00% | -2.74% | -218.42% | 188.31% | -2539.34% |
Solara Active Pharma Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2019-2020 to 2023-2024.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -7% |
| TTM: | -4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | -9% |
| 1 Year: | 41% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -2% |
| 3 Years: | -11% |
| Last Year: | -34% |
Last Updated: Unknown
Balance Sheet
Last Updated: November 14, 2024, 7:37 pm
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 25 | 26 | 27 | 36 | 36 | 36 | 36 | 40 |
| Reserves | 739 | 930 | 1,059 | 1,553 | 1,489 | 1,464 | 898 | 1,046 |
| Borrowings | 633 | 538 | 722 | 621 | 1,037 | 1,013 | 1,012 | 840 |
| Other Liabilities | 425 | 466 | 346 | 404 | 383 | 386 | 406 | 364 |
| Total Liabilities | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,290 |
| Fixed Assets | 1,086 | 1,218 | 1,397 | 1,382 | 1,356 | 1,364 | 1,268 | 1,231 |
| CWIP | 71 | 40 | 40 | 88 | 239 | 238 | 256 | 272 |
| Investments | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 2 |
| Other Assets | 663 | 701 | 716 | 1,144 | 1,350 | 1,295 | 825 | 786 |
| Total Assets | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,290 |
Below is a detailed analysis of the balance sheet data for Solara Active Pharma Sciences Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2024, the value is ₹40.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹36.00 Cr. (Mar 2024) to ₹40.00 Cr., marking an increase of 4.00 Cr..
- For Reserves, as of Sep 2024, the value is ₹1,046.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹898.00 Cr. (Mar 2024) to ₹1,046.00 Cr., marking an increase of 148.00 Cr..
- For Borrowings, as of Sep 2024, the value is ₹840.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹1,012.00 Cr. (Mar 2024) to ₹840.00 Cr., marking a decrease of 172.00 Cr..
- For Other Liabilities, as of Sep 2024, the value is ₹364.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹406.00 Cr. (Mar 2024) to ₹364.00 Cr., marking a decrease of 42.00 Cr..
- For Total Liabilities, as of Sep 2024, the value is ₹2,290.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹2,351.00 Cr. (Mar 2024) to ₹2,290.00 Cr., marking a decrease of 61.00 Cr..
- For Fixed Assets, as of Sep 2024, the value is ₹1,231.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹1,268.00 Cr. (Mar 2024) to ₹1,231.00 Cr., marking a decrease of 37.00 Cr..
- For CWIP, as of Sep 2024, the value is ₹272.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹256.00 Cr. (Mar 2024) to ₹272.00 Cr., marking an increase of 16.00 Cr..
- For Investments, as of Sep 2024, the value is ₹2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹2.00 Cr..
- For Other Assets, as of Sep 2024, the value is ₹786.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹825.00 Cr. (Mar 2024) to ₹786.00 Cr., marking a decrease of 39.00 Cr..
- For Total Assets, as of Sep 2024, the value is ₹2,290.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹2,351.00 Cr. (Mar 2024) to ₹2,290.00 Cr., marking a decrease of 61.00 Cr..
Notably, the Reserves (₹1,046.00 Cr.) exceed the Borrowings (840.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | -576.00 | -325.00 | -462.00 | -235.00 | 80.00 | 133.00 | -96.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 184 | 76 | 63 | 109 | 141 | 136 | 99 |
| Inventory Days | 252 | 111 | 170 | 149 | 321 | 258 | 163 |
| Days Payable | 420 | 127 | 132 | 156 | 154 | 142 | 142 |
| Cash Conversion Cycle | 16 | 60 | 101 | 102 | 308 | 252 | 120 |
| Working Capital Days | 107 | 34 | 67 | 118 | 251 | 213 | 126 |
| ROCE % | 10% | 12% | 15% | -0% | 2% | -9% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Aditya Birla Sun Life Flexi Cap Fund | 420,000 | 0.08 | 15.17 | 130,000 | 2025-03-10 | 223.08% |
| Aditya Birla Sun Life Midcap Fund | 130,000 | 0.09 | 4.7 | 130,000 | 2025-03-10 | 0% |
| Aditya Birla Sun Life Manufacturing Equity Fund | 65,000 | 0.29 | 2.35 | 130,000 | 2025-03-10 | -50% |
| Motilal Oswal S&P BSE Healthcare ETF | 183 | 0.07 | 0.01 | 130,000 | 2025-03-10 | -99.86% |
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -157.62 | -6.16 | -16.18 | 69.00 | 44.29 |
| Diluted EPS (Rs.) | -157.62 | -6.16 | -16.18 | 64.53 | 42.82 |
| Cash EPS (Rs.) | -128.79 | 24.70 | 15.01 | 91.87 | 77.72 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 260.16 | 417.35 | 424.22 | 443.42 | 370.29 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 260.16 | 417.35 | 424.22 | 443.42 | 370.29 |
| Revenue From Operations / Share (Rs.) | 358.03 | 401.06 | 352.32 | 450.13 | 492.27 |
| PBDIT / Share (Rs.) | -24.95 | 43.45 | 27.77 | 115.43 | 106.88 |
| PBIT / Share (Rs.) | -53.65 | 12.57 | -3.42 | 85.18 | 71.81 |
| PBT / Share (Rs.) | -135.67 | -12.45 | -25.31 | 61.66 | 42.80 |
| Net Profit / Share (Rs.) | -157.49 | -6.18 | -16.19 | 61.62 | 42.65 |
| NP After MI And SOA / Share (Rs.) | -157.61 | -6.16 | -16.15 | 61.64 | 42.69 |
| PBDIT Margin (%) | -6.96 | 10.83 | 7.88 | 25.64 | 21.71 |
| PBIT Margin (%) | -14.98 | 3.13 | -0.97 | 18.92 | 14.58 |
| PBT Margin (%) | -37.89 | -3.10 | -7.18 | 13.69 | 8.69 |
| Net Profit Margin (%) | -43.98 | -1.54 | -4.59 | 13.68 | 8.66 |
| NP After MI And SOA Margin (%) | -44.02 | -1.53 | -4.58 | 13.69 | 8.67 |
| Return on Networth / Equity (%) | -60.75 | -1.47 | -3.81 | 13.93 | 11.57 |
| Return on Capital Employeed (%) | -17.42 | 2.51 | -0.65 | 16.76 | 13.54 |
| Return On Assets (%) | -24.13 | -0.76 | -1.96 | 8.47 | 5.32 |
| Long Term Debt / Equity (X) | 0.11 | 0.15 | 0.18 | 0.09 | 0.23 |
| Total Debt / Equity (X) | 1.07 | 0.66 | 0.67 | 0.32 | 0.59 |
| Asset Turnover Ratio (%) | 0.49 | 0.49 | 0.45 | 0.67 | 0.64 |
| Current Ratio (X) | 0.64 | 1.08 | 1.16 | 1.34 | 0.92 |
| Quick Ratio (X) | 0.35 | 0.57 | 0.61 | 0.96 | 0.53 |
| Inventory Turnover Ratio (X) | 1.66 | 1.37 | 1.97 | 2.38 | 2.49 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | -18.53 | 8.90 | 13.63 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 19.90 | 5.97 | 7.48 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 118.53 | 91.10 | 86.37 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 80.10 | 94.03 | 92.52 |
| Interest Coverage Ratio (X) | -0.85 | 1.74 | 1.33 | 4.91 | 3.68 |
| Interest Coverage Ratio (Post Tax) (X) | -2.58 | 0.75 | 0.27 | 3.62 | 2.47 |
| Enterprise Value (Cr.) | 2334.27 | 2176.74 | 3374.17 | 5329.56 | 1723.87 |
| EV / Net Operating Revenue (X) | 1.81 | 1.51 | 2.66 | 3.30 | 1.30 |
| EV / EBITDA (X) | -25.99 | 13.92 | 33.74 | 12.85 | 6.01 |
| MarketCap / Net Operating Revenue (X) | 1.04 | 0.81 | 1.89 | 3.10 | 0.90 |
| Retention Ratios (%) | 0.00 | 0.00 | 118.53 | 91.09 | 86.36 |
| Price / BV (X) | 1.44 | 0.78 | 1.57 | 3.15 | 1.20 |
| Price / Net Operating Revenue (X) | 1.04 | 0.81 | 1.89 | 3.10 | 0.90 |
| EarningsYield | -0.42 | -0.01 | -0.02 | 0.04 | 0.09 |
After reviewing the key financial ratios for Solara Active Pharma Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 24, the value is -157.62. This value is below the healthy minimum of 5. It has decreased from -6.16 (Mar 23) to -157.62, marking a decrease of 151.46.
- For Diluted EPS (Rs.), as of Mar 24, the value is -157.62. This value is below the healthy minimum of 5. It has decreased from -6.16 (Mar 23) to -157.62, marking a decrease of 151.46.
- For Cash EPS (Rs.), as of Mar 24, the value is -128.79. This value is below the healthy minimum of 3. It has decreased from 24.70 (Mar 23) to -128.79, marking a decrease of 153.49.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 260.16. It has decreased from 417.35 (Mar 23) to 260.16, marking a decrease of 157.19.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 260.16. It has decreased from 417.35 (Mar 23) to 260.16, marking a decrease of 157.19.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 358.03. It has decreased from 401.06 (Mar 23) to 358.03, marking a decrease of 43.03.
- For PBDIT / Share (Rs.), as of Mar 24, the value is -24.95. This value is below the healthy minimum of 2. It has decreased from 43.45 (Mar 23) to -24.95, marking a decrease of 68.40.
- For PBIT / Share (Rs.), as of Mar 24, the value is -53.65. This value is below the healthy minimum of 0. It has decreased from 12.57 (Mar 23) to -53.65, marking a decrease of 66.22.
- For PBT / Share (Rs.), as of Mar 24, the value is -135.67. This value is below the healthy minimum of 0. It has decreased from -12.45 (Mar 23) to -135.67, marking a decrease of 123.22.
- For Net Profit / Share (Rs.), as of Mar 24, the value is -157.49. This value is below the healthy minimum of 2. It has decreased from -6.18 (Mar 23) to -157.49, marking a decrease of 151.31.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -157.61. This value is below the healthy minimum of 2. It has decreased from -6.16 (Mar 23) to -157.61, marking a decrease of 151.45.
- For PBDIT Margin (%), as of Mar 24, the value is -6.96. This value is below the healthy minimum of 10. It has decreased from 10.83 (Mar 23) to -6.96, marking a decrease of 17.79.
- For PBIT Margin (%), as of Mar 24, the value is -14.98. This value is below the healthy minimum of 10. It has decreased from 3.13 (Mar 23) to -14.98, marking a decrease of 18.11.
- For PBT Margin (%), as of Mar 24, the value is -37.89. This value is below the healthy minimum of 10. It has decreased from -3.10 (Mar 23) to -37.89, marking a decrease of 34.79.
- For Net Profit Margin (%), as of Mar 24, the value is -43.98. This value is below the healthy minimum of 5. It has decreased from -1.54 (Mar 23) to -43.98, marking a decrease of 42.44.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is -44.02. This value is below the healthy minimum of 8. It has decreased from -1.53 (Mar 23) to -44.02, marking a decrease of 42.49.
- For Return on Networth / Equity (%), as of Mar 24, the value is -60.75. This value is below the healthy minimum of 15. It has decreased from -1.47 (Mar 23) to -60.75, marking a decrease of 59.28.
- For Return on Capital Employeed (%), as of Mar 24, the value is -17.42. This value is below the healthy minimum of 10. It has decreased from 2.51 (Mar 23) to -17.42, marking a decrease of 19.93.
- For Return On Assets (%), as of Mar 24, the value is -24.13. This value is below the healthy minimum of 5. It has decreased from -0.76 (Mar 23) to -24.13, marking a decrease of 23.37.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.11. This value is below the healthy minimum of 0.2. It has decreased from 0.15 (Mar 23) to 0.11, marking a decrease of 0.04.
- For Total Debt / Equity (X), as of Mar 24, the value is 1.07. This value exceeds the healthy maximum of 1. It has increased from 0.66 (Mar 23) to 1.07, marking an increase of 0.41.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.49. There is no change compared to the previous period (Mar 23) which recorded 0.49.
- For Current Ratio (X), as of Mar 24, the value is 0.64. This value is below the healthy minimum of 1.5. It has decreased from 1.08 (Mar 23) to 0.64, marking a decrease of 0.44.
- For Quick Ratio (X), as of Mar 24, the value is 0.35. This value is below the healthy minimum of 1. It has decreased from 0.57 (Mar 23) to 0.35, marking a decrease of 0.22.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.66. This value is below the healthy minimum of 4. It has increased from 1.37 (Mar 23) to 1.66, marking an increase of 0.29.
- For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 24, the value is -0.85. This value is below the healthy minimum of 3. It has decreased from 1.74 (Mar 23) to -0.85, marking a decrease of 2.59.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is -2.58. This value is below the healthy minimum of 3. It has decreased from 0.75 (Mar 23) to -2.58, marking a decrease of 3.33.
- For Enterprise Value (Cr.), as of Mar 24, the value is 2,334.27. It has increased from 2,176.74 (Mar 23) to 2,334.27, marking an increase of 157.53.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.81. This value is within the healthy range. It has increased from 1.51 (Mar 23) to 1.81, marking an increase of 0.30.
- For EV / EBITDA (X), as of Mar 24, the value is -25.99. This value is below the healthy minimum of 5. It has decreased from 13.92 (Mar 23) to -25.99, marking a decrease of 39.91.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.04. This value is within the healthy range. It has increased from 0.81 (Mar 23) to 1.04, marking an increase of 0.23.
- For Retention Ratios (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Price / BV (X), as of Mar 24, the value is 1.44. This value is within the healthy range. It has increased from 0.78 (Mar 23) to 1.44, marking an increase of 0.66.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.04. This value is within the healthy range. It has increased from 0.81 (Mar 23) to 1.04, marking an increase of 0.23.
- For EarningsYield, as of Mar 24, the value is -0.42. This value is below the healthy minimum of 5. It has decreased from -0.01 (Mar 23) to -0.42, marking a decrease of 0.41.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Solara Active Pharma Sciences Ltd:
- Net Profit Margin: -43.98%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -17.42% (Industry Average ROCE: 16%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -60.75% (Industry Average ROE: 16.32%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -2.58
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.35
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 42.42)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.07
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -43.98%
About the Company - Qualitative Analysis
Solara Active Pharma Sciences Ltd. is a Public Limited Listed company incorporated on 23/02/2017 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24230MH2017PLC291636 and registration number is 291636. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 1288.92 Cr. and Equity Capital is Rs. 36.00 Cr. for the Year ended 31/03/2024.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 201, Devavrata, Sector 17, Vashi, New Mumbai Maharashtra 400703 | investors@solara.co.in http://www.solara.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. R Ramakrishnan | Chairman & Ind.Director |
| Mr. Poorvank Purohit | Managing Director & CEO |
| Mr. Mohan Muthunarayanan | COO & Executive Director |
| Mr. Manish Gupta | Non Executive Director |
| Mr. Kartheek Chintalapati Raju | Non Executive Director |
| Mr. Arun Kumar | Non Executive Director |
| Dr. Kausalya Santhanam | Independent Director |
| Mr. Rajiv Vijay Nabar | Independent Director |
| Mr. Rajendra Kumar Srivastava | Independent Director |
FAQ
What is the latest intrinsic value of Solara Active Pharma Sciences Ltd?
The latest intrinsic value of Solara Active Pharma Sciences Ltd as on 12 March 2025 is ₹1234.22, which is 136.44% higher than the current market price of 522.00, indicating the stock is undervalued by 136.44%. The intrinsic value of Solara Active Pharma Sciences Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹2,204 Cr. and recorded a high/low of ₹886/327 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹1,046 Cr and total liabilities of ₹2,290 Cr.
What is the Market Cap of Solara Active Pharma Sciences Ltd?
The Market Cap of Solara Active Pharma Sciences Ltd is 2,204 Cr..
What is the current Stock Price of Solara Active Pharma Sciences Ltd as on 12 March 2025?
The current stock price of Solara Active Pharma Sciences Ltd as on 12 March 2025 is ₹522.
What is the High / Low of Solara Active Pharma Sciences Ltd stocks in FY 2024-2025?
In FY 2024-2025, the High / Low of Solara Active Pharma Sciences Ltd stocks is ₹886/327.
What is the Stock P/E of Solara Active Pharma Sciences Ltd?
The Stock P/E of Solara Active Pharma Sciences Ltd is .
What is the Book Value of Solara Active Pharma Sciences Ltd?
The Book Value of Solara Active Pharma Sciences Ltd is 301.
What is the Dividend Yield of Solara Active Pharma Sciences Ltd?
The Dividend Yield of Solara Active Pharma Sciences Ltd is 0.00 %.
What is the ROCE of Solara Active Pharma Sciences Ltd?
The ROCE of Solara Active Pharma Sciences Ltd is 8.67 %.
What is the ROE of Solara Active Pharma Sciences Ltd?
The ROE of Solara Active Pharma Sciences Ltd is 33.5 %.
What is the Face Value of Solara Active Pharma Sciences Ltd?
The Face Value of Solara Active Pharma Sciences Ltd is 10.0.